Experimental hepatitis b drug shows promise but study halted
NCT ID NCT02065336
First seen Jan 15, 2026 · Last updated May 16, 2026 · Updated 16 times
Summary
This study tested an experimental drug called ARC-520, given with a standard antiviral (entecavir), to lower hepatitis B surface antigen levels in people with chronic hepatitis B. The trial included 58 participants and was stopped early. The goal was to control the virus, not cure it, as patients needed to stay on medication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS B, CHRONIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site 1
Pokfulam, Hong Kong
-
Research Site 2
Shatin, Hong Kong
Conditions
Explore the condition pages connected to this study.